2007 Healthcare Safety 
pharmaphorum
DECEMBER 14, 2022
Tentative approval means Lumryz has satisfied all the FDA requirements for efficacy, safety, and quality standards, but it can’t be fully approved until a patent or other exclusivity expires. Furthermore, Molina stated Jazz “suppressed generic competition and raised the price of Xyrem 841% between 2007 and 2014.” About the author.
European Pharmaceutical Review
OCTOBER 17, 2024
In the UK, ARS Pharmaceuticals anticipates filing for approval from the Medicines and Healthcare products Regulatory Agency (MHRA) by Q4 2024, under their Mutual Recognition Process A, where MHRA will review and approve EURneffy based on the EMA approval within 60 days of filing. 2007; 2(1):5-11. 2022 ; 17(11). Hand (N Y).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JUNE 22, 2023
According to the information sharing platform AMR Insights , AMR is considered one of the biggest global threats to health and food safety. About the interviewees Courtney Soulsby is the Global Director, Healthcare Sustainability for BSI. Combatting AMR calls for international cooperation based on the One Health Approach.
Pharmaceutical Technology
FEBRUARY 24, 2023
The products that are authorised in EU are largely the same as other regions,” argued European Commission Directorate-General for Health and Food Safety Florian Schmidt, during the same online event. But others do not accept that the EU is less competitive for the pharma industry than North America and Asia. You can compare timelines.
Pharmaceutical Technology
OCTOBER 13, 2022
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Colonis Pharma’s melatonin oral solution for the treatment of sleep-onset insomnia in children and adolescents with attention-deficit hyperactivity disorder (ADHD). Reiter adds, "Most children have high levels of melatonin in their blood at night.
Pharmaceutical Technology
OCTOBER 5, 2008
According to market intelligence provider Pharmaceutical Insights, Japan’s $6m generic drug sector is currently experiencing a renaissance, primarily because the government wants to control healthcare costs. “Ranbaxy led the way with eight acquisitions and is aspiring to be a $2bn company by 2007.”
pharmaphorum
NOVEMBER 30, 2022
Discussing how the energy crisis is squeezing budgets and how healthcare costs have become higher than ever, Moore stated that the time is right for high-value engagement. Founded in 2007 by Peter Gassner, a luminary of Silicon Valley with a net worth of circa $5.25 The race to high-value engagement’.
Expert insights. Personalized for you.
116 
Let's personalize your content